Comparing Outcomes From Clinical Studies of Oral Disease-Modifying Therapies (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Relapsing MS: Assessing Absolute Differences Using a Number Needed to Treat Analysis
Multiple Sclerosis and Related Disorders - United States
doi 10.1016/j.msard.2016.10.010
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2016
Authors
Publisher
Elsevier BV